
Reset all filters
01 2SPINRAZA royalties
02 9Spinraza
03 3Spinraza Royalties
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2020 Revenue in Millions : 2,052
2019 Revenue in Millions : 2,097
Growth (%) : -2
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2020 Revenue in Millions : 287
2019 Revenue in Millions : 293
Growth (%) : -2
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2021 Revenue in Millions : 1,905
2020 Revenue in Millions : 2,052
Growth (%) : -7
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2021 Revenue in Millions : 268
2020 Revenue in Millions : 287
Growth (%) : -7
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2022 Revenue in Millions : 242
2021 Revenue in Millions : 268
Growth (%) : -10
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2022 Revenue in Millions : 1,794
2021 Revenue in Millions : 1,905
Growth (%) : -6
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2023 Revenue in Millions : 240
2022 Revenue in Millions : 242
Growth (%) : -1
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2023 Revenue in Millions : 1,741
2022 Revenue in Millions : 1,794
Growth (%) : -3
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2024 Revenue in Millions : 216
2023 Revenue in Millions : 240
Growth (%) : -10
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2024 Revenue in Millions : 1,573
2023 Revenue in Millions : 1,741
Growth (%) : -10